Alliance to Develop Clinical Diagnostics

(Research Triangle Park, NC, USA) and Medical & Biological Laboratories Co., Ltd. (MBL, Nagoya, Japan). The alliance combines MBL's product development and commercialization expertise with the target discovery process and systems biology data of Ribonomics.

Under the terms of the agreement, Ribonomics will use its proprietary RAS platform technology to discover new diagnostic biomarkers that rapidly and accurately detect disease. In return for an upfront technology fee, MBL has secured the first right of access to develop, manufacture, and commercialize products directed at disease markers discovered by Ribonomics. In cases where MBL elects to develop a product covered by the collaboration, Ribonomics will receive licensing fees as well as milestone payments and royalties, as specified.

"This collaboration will benefit MBL incredibly in that it will allow MBL to gain access to novel diagnostic targets discovered by Ribonomics and enable MBL to quickly advance the development of research and diagnostic products,” said Sachiko Suno, chairman of MBL.





Related Links:
Ribonomics
MBL